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AbstrAct
Objective Epidemiological data for primary discoid 
lupus erythematosus (pDLE) remain limited, particularly 
for racial/ethnic populations in the USA. The Manhattan 
Lupus Surveillance Program (MLSP) is a population- based 
retrospective registry of cases with SLE and related 
diseases including pDLE in Manhattan and was used to 
provide estimates of the prevalence and incidence of pDLE 
across major racial/ethnic populations.
Methods MLSP cases were identified from 
rheumatologists, hospitals and population databases. Two 
case definitions were used for pDLE: the primary case 
definition which was any physician diagnosis found in the 
chart and a secondary case definition which was limited to 
cases diagnosed by a rheumatologist and/or dermatologist. 
Rates among Manhattan residents were age- adjusted, and 
capture–recapture analyses were conducted to assess 
case under- ascertainment.
Results Based on the primary definition, age- adjusted 
overall prevalence and incidence rates of pDLE among 
Manhattan residents were 6.5 and 0.8 per 100 000 person- 
years, which increased to 9.0 and 1.3 after capture–
recapture adjustment. Prevalence and incidence rates 
were approximately two and six times higher, respectively, 
among women compared with men (p<0.0001). Higher 
prevalence was also found among non- Latino blacks (23.5) 
and Latinos (8.2) compared with non- Latino whites (1.8) 
and non- Latino Asians (0.6) (p<0.0001). Incidence was 
highest among non- Latino blacks (2.4) compared with 
all other racial/ethnic groups. Similar relationships were 
observed for the secondary case definition.
Conclusion Data from the MLSP provide epidemiological 
estimates for pDLE among the major racial/ethnic 
populations in the USA and reveal disparities in pDLE 
prevalence and incidence by sex and race/ethnicity among 
Manhattan residents.
IntROduCtIOn
Discoid lupus erythematosus (DLE) is one 
of the most common cutaneous manifesta-
tions of SLE, with recent population- based 
studies estimating it occurs in approximately 
12.4%–15.0% of incident SLE cases1–3 and 
in approximately 16.6%–24.3% of prevalent 
cases.1 3 4 The highest rates of DLE in patients 
with SLE are seen among black patients.1–4 
DLE is associated with considerable morbidity, 
as it tends to occur on the face, scalp and ears, 
and is associated with scarring and permanent 
alopecia.5 6 DLE can also occur in the absence 
of SLE, referred to as primary DLE (pDLE). 
The extant epidemiological data on pDLE 
remain limited with few published estimates 
for the general population and scant data for 
racial/ethnic populations in the USA.7
The Manhattan Lupus Surveillance 
Program (MLSP) is one of five Centers for 
Disease Control and Prevention (CDC)–
funded population- based registries composed 
of patients with SLE and related diseases.1–4 8 
Recently, the Georgia Lupus Registry (GLR) 
reported an overall age- adjusted incidence 
of pDLE of 3.7 per 100 000 person- years, with 
a black:white ratio of 5.3.7 We used MLSP 
data to provide estimates of the prevalence 
and incidence of pDLE during 2007 and 
2007–2009, respectively, in Manhattan which 
is characterised by a more diverse population 
(non- Latino black, Latino, non- Latino Asian, 
non- Latino white) than the GLR.
MethOds
Manhattan Lupus surveillance Program
Details on the MLSP have been previously 
reported.1 9 In brief, medical records were 
reviewed under the health surveillance 
exemption to HIPAA privacy rules (45 CFR 
§ 164.512(b)) and as authorised by New York 
City Charter Sections 556(c)(2) and (d)(2) 
with no potential cases being contacted for this 
project. The MLSP was deemed surveillance 
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that did not require institutional review board (IRB) 
review by IRBs at the CDC, the New York City Department 
of Health and Mental Hygiene (DOHMH) and the New 
York University School of Medicine. Additional IRB appli-
cations were completed and submitted to independent 
case- finding sources when requested. The DOHMH IRB 
reviewed and approved secondary analyses on a de- identi-
fied dataset including the analyses presented here.
The surveillance period for the MLSP was 1 January 
2007 through 31 December 2009 with Manhattan being 
chosen for reasons previously described.1 Based on 2010 
US Census data, there were 1 585 873 persons residing 
in Manhattan (48% non- Latino white, 25% Latino, 13% 
non- Latino black, 11% non- Latino Asian).10
Case ascertainment, data collection and quality control of 
data entry
Case- finding sources for the MLSP included rheuma-
tologists’ practices (including paediatric rheumatolo-
gists), hospitals (rarely including associated dermatology 
clinics), and administrative hospitalisation discharge and 
death registry databases.1 Sources were queried retro-
spectively to identify patients who lived in Manhattan 
with the following International Classification of Disease 
Ninth Revision Clinical Modification (ICD- 9CM) billing 
codes: 710.0 (SLE), 695.4 (DLE), 710.8 (other specified 
connective tissue disease), 710.9 (unspecified connec-
tive tissue disease) and 710.2 (Sicca syndrome, which is 
used for Sjögren’s syndrome). Charts for every patient 
who had one of the respective ICD- 9CM codes and was 
confirmed to live in Manhattan were fully abstracted 
and final diagnosis and date of diagnosis were coded. In 
addition, the type of physician (rheumatologist, derma-
tologist) making the diagnosis was also coded. Abstrac-
tion was performed by trained abstractors with medical 
degrees who underwent extensive training and routine 
quality assurance; abstraction was completed in 90.5% of 
hospitals and 75.8% of rheumatologists’ practices.1
Case definitions
Our primary case definition was any statement by a physi-
cian that the patient carries a diagnosis of pDLE found in 
the chart. The diagnosis could be stated by a rheumatolo-
gist (both as inpatient or outpatient) or dermatology note 
(if seen as an inpatient, or if a consult note was found 
in a rheumatologist’s chart, or if found in a hospital- 
associated dermatology clinic). In addition, pDLE would 
be included if listed under medical history if a patient was 
admitted for a completely different reason. Our primary 
case definition was purposefully broad in an effort to 
capture as many cases as possible to get an estimate of the 
burden of the disease.
Our more restrictive secondary definition required 
evidence that the diagnosis was stated by a rheumatolo-
gist or dermatologist. Given the MLSP did not approach 
dermatology practices and only rarely had access to 
hospital- associated dermatology clinics as a case- finding 
source, we did not want to further underestimate the 
burden of DLE by also requiring evidence of a biopsy, 
which is not always performed.7 Thus, we did not require 
evidence of a compatible diagnostic biopsy for either 
definition. Cases that met American College of Rheuma-
tology (ACR) Classification criteria for SLE11 12 were not 
considered to be pDLE cases. In addition, we excluded 
any case that carried a final diagnosis of SLE based on a 
rheumatologist’s note only and also had evidence of DLE 
but did not fulfil ACR criteria.
statistical analysis
Prevalent cases were new or existing pDLE cases residing 
in Manhattan from 1 January to 31 December 2007. 
Incident cases were those residing in Manhattan and 
first diagnosed with pDLE from 1 January 2007 through 
31 December 2009. Denominators were calculated 
from DOHMH intercensal population estimates for 
Manhattan.10
Rates overall, by sex and by race/ethnicity were calcu-
lated per 100 000 person- years and age- adjusted to the 
USA 2000 standard population.13 Due to small counts, we 
calculated CIs using the gamma method.14 Data on race 
and Latino ethnicity were collected separately, but this 
information was used to assign cases into five mutually 
exclusive race/ethnicity categories: Latino, non- Latino 
white, non- Latino black, non- Latino Asian and non- Latino 
other (including more than one race). Differences by sex 
and race/ethnicity were assessed using χ2 tests or Fisher’s 
exact tests. If a significant difference was found by race/
ethnicity, pairwise differences were then evaluated using 
z- tests assuming the Poisson distribution and statistical 
significance at 0.05, with Bonferroni correction to 0.008. 
Capture–recapture analyses were performed15 16 to esti-
mate case under- ascertainment,1 with log- linear models 
fit separately for incident and prevalent cases by race/
ethnicity. We fit various models that addressed poten-
tial violation of the homogeneity assumption of capture 
probability and identified the best- fitting model using the 
Akaike information criterion. Then we used these model 
estimates to calculate revised prevalence and incidence 
rates.15 16
Frequency and location of discoid rash information 
was described only among cases meeting the secondary 
definition, as these cases with evidence of diagnosis by a 
rheumatologist or dermatologist were more likely to have 
accompanying descriptive evidence in the record.
All analyses were completed using SAS V.9.4 (SAS Insti-
tute, Cary, North Carolina, USA) except for capture–
recapture analysis that was completed using RStudio 
Server with R V.3.5.2 (R Foundation for Statistical 
Computing, Vienna, Austria).
ResuLts
Prevalence rates for dLe
Using the primary case definition, a total of 110 cases had 
a diagnosis of pDLE, with most (71) having evidence of a 
diagnosis by a rheumatologist or dermatologist (table 1). 
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Table 1 Evidence of a diagnosis of primary discoid lupus erythematosus among prevalent and incident cases by physician 
type
Primary case definition
Prevalence
n=110
Incidence
n=41
No rheumatologist, dermatologist stated the final diagnosis 37 15
One or more rheumatologists stated the final diagnosis 21 10
One or more dermatologists stated the final diagnosis 32 8
A rheumatologist and/or dermatologist stated the final diagnosis 18 8
A pathologist stated the final diagnosis 2 0
Table 2 Crude and adjusted prevalence rates of primary discoid lupus erythematosus (pDLE) among Manhattan residents, 
2007, overall and by sex and race/ethnicity
Crude rate
(95% CI)
Age- adjusted rate 
(95% CI) χ2 p value
Capture–recapture 
adjusted rate
Primary definition pDLE—any MD diagnosis
  Total 7.0 (5.7 to 8.3) 6.5 (5.2 to 7.7) 9.0 (7.0 to 11.0)
   Male 3.9 (2.6 to 5.6) 3.7 (2.4 to 5.3) <0.0001
   Female 9.7 (7.7 to 12.0) 8.7 (6.9 to 10.9)
  Race/ethnicity <0.0001*
   Non- Latino white 2.1 (1.2 to 3.4) 1.8 (1.0 to 2.9) 2.5 (2.0 to 2.9)
   Non- Latino black 25.2 (18.9 to 32.8) 23.5 (17.6 to 30.7) 34.2 (30.3 to 38.1)
   Latino 7.8 (5.4 to 11.1) 8.2 (5.6 to 11.6) 10.7 (9.3 to 12.0)
   Non- Latino Asian 0.6 (0.0 to 3.2) 0.6 (0.0 to 3.5) 0.9 (0.0 to 1.7)
   
Secondary definition pDLE—rheumatologist or dermatologist diagnosis
  Total 4.5 (3.5 to 5.7) 4.2 (3.3 to 5.3) 6.6 (3.2 to 10.1)
   Male 2.6 (1.5 to 4.0) 2.4 (1.4 to 3.8) 0.0006
   Female 6.2 (4.6 to 8.1) 5.7 (4.2 to 7.5)
  Race/ethnicity <0.0001*
   Non- Latino white 0.9 (0.4 to 1.9) 0.8 (0.3 to 1.6) 1.6 (−0.6 to 3.8)
   Non- Latino black 18.2 (12.9 to 24.9) 17.2 (12.2 to 23.5) 25.8 (21.2 to 30.4)
    Latino 4.7 (2.8 to 7.3) 4.9 (2.9 to 7.6) 7.7 (4.5 to 11.0)
   Non- Latino Asian 0.6 (0.0 to 3.2) 0.6 (0.0 to 3.5) 0.9 (0.0 to 1.7)
   
Cases exclude those meeting American College of Rheumatology criteria for SLE.
Rates are per 100 000 Manhattan residents. Denominator data are based on 2007–2009 intercensal population estimates from the New York 
City Department of Health and Mental Hygiene Bureau of Epi Services (2000–2014 files).
Data are age- adjusted to the US 2000 Standard Population.
Cases were assigned to one of five mutually exclusive race/ethnicity categories: non- Latino white, non- Latino black, non- Latino Asian, Latino 
and non- Latino other. Non- Latino cases identified with more than one race were categorised as non- Latino other; rates were not calculated 
for this group.
*Non- Latino blacks differed from non- Latino whites, Latinos and non- Latino Asians. Latinos also differed from non- Latino whites and non- 
Latino Asians. Non- Latino whites did not significantly differ from non- Latino Asians.
The crude and age- adjusted prevalence of pDLE by this 
definition were 7.0 (95% CI 5.7 to 8.3) and 6.5 (95% 
CI 5.2 to 7.7) per 100 000 person- years (table 2). Age- 
adjusted rates were approximately two times higher 
among women compared with men (p<0.0001). The 
age- adjusted prevalence of pDLE also differed by race/
ethnicity (p<0.0001) and was significantly higher among 
non- Latino blacks (23.5) and Latinos (8.2) compared 
with non- Latino whites (1.8) and non- Latino Asians (0.6). 
Capture–recapture estimated an additional 9.8 cases of 
pDLE, indicating that 8.2% of cases may have been 
missed. With this adjustment, the overall prevalence of 
pDLE increased to 9.0 (95% CI 7.0 to 11.0) and among 
non- Latino blacks increased to 34.2. (95% CI 30.3 to 
38.1). Using the secondary (more restrictive) case defi-
nition for pDLE lowered the crude and age- adjusted 
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Table 3 Crude and adjusted incidence rates of primary discoid lupus erythematosus (pDLE) among Manhattan residents, 
2007–2009, overall and by sex and race/ethnicity
Crude rate (95% CI)
Age- adjusted rate 
(95% CI) χ2 p value
Capture–recapture 
adjusted rate
Primary definition pDLE—any MD diagnosis
  Total 0.9 (0.6 to 1.2) 0.8 (0.6 to 1.1) 1.3 (0.6 to 2.0)
   Male 0.3 (0.1 to 0.7) 0.3 (0.1 to 0.6) <0.0001
   Female 1.4 (0.9 to 1.9) 1.3 (0.9 to 1.8)
Race/ethnicity <0.0001*
   Non- Latino white 0.3 (0.1 to 0.6) 0.3 (0.1 to 0.6) 0.4 (0.3 to 0.4)
   Non- Latino black 2.4 (1.3 to 3.9) 2.3 (1.3 to 3.8) 4.0 (2.1 to 5.8)
   Latino 1.0 (0.5 to 1.7) 1.0 (0.5 to 1.7) 1.5 (1.0 to 2.0)
   Non- Latino Asian 0.6 (0.1 to 1.7) 0.6 (0.1 to 1.7) 1.1 (-0.5 to 2.7)
   
Secondary definition pDLE—rheumatologist or dermatologist diagnosis
  Total 0.5 (0.4 to 0.8) 0.5 (0.3 to 0.7) 0.9 (0.2 to 1.5)
   Male 0.1 (0.0 to 0.4) 0.1 (0.0 to 0.3) 0.0002
   Female 0.9 (0.6 to 1.4) 0.8 (0.5 to 1.3)
  Race/ethnicity <0.0001†
   Non- Latino white 0.2 (0.1 to 0.5) 0.2 (0.0 to 0.4) 0.2 (0.1 to 0.3)
   Non- Latino black 1.9 (1.0 to 3.3) 1.8 (0.9 to 3.2) 3.2 (1.8 to 4.6)
   Latino 0.5 (0.2 to 1.1) 0.5 (0.2 to 1.0) 0.9 (-0.1 to 1.8)
   Non- Latino Asian 0.6 (0.1 to 1.7) 0.6 (0.1 to 1.7) 0.9 (-0.5 to 2.3)
  
Cases exclude those meeting American College of Rheumatology criteria for SLE.
Rates are per 100 000 Manhattan residents. Denominator data are based on 2007–2009 intercensal population estimates from the New York 
City Department of Health and Mental Hygiene Bureau of Epi Services (2000–2014 files).
Data are age- adjusted to the US 2000 Standard Population.
Cases were assigned to one of five mutually exclusive race/ethnicity categories: non- Latino white, non- Latino black, non- Latino Asian, Latino 
and non- Latino other. Non- Latino cases identified with more than one race were categorised as non- Latino other; rates were not calculated 
for this group.
*Non- Latino blacks differed from non- Latino whites and non- Latino Asians. Latinos also differed from non- Latino whites and non- Latino 
Asians.
†Non- Latino blacks differed from non- Latino whites and Latinos.
prevalence to 4.5 (95% CI 3.5 to 5.7) and 4.2 (95% CI 3.3 
to 5.3) per 100 000 person- years (table 2). Similar dispari-
ties were seen, with higher rates among women compared 
with men (p=0.0006) as well as higher rates among non- 
Latino blacks and Hispanics (p<0.0001, table 2).
The average ages (±SD) among women and men in 
2007 meeting the primary case definition were 53.5 
(±17.5) and 40.4 (±13.6) years, respectively. The average 
age of pDLE cases was highest among non- Latino whites 
(60.6±19.3) followed by Latinos (53.8±18.0) and non- 
Latino blacks (45.0±15.1). Age- specific prevalence rates 
were higher among cases aged 40–59 (7.7, 95% CI 5.3 to 
10.9) and 60 and older (6.4, 95% CI 3.8 to 10.1) compared 
with those aged 20–39 (3.2, 95% CI 1.9 to 4.9).
Among prevalent cases meeting the secondary case 
definition, discoid rash was localised above the neck 
for 39.4% and generalised for 28.2%. Almost one- third 
(32.4%) of cases had no further information available on 
rash location. Biopsy confirmation of pDLE was rare, with 
evidence found for only 2.8% of prevalent pDLE cases. 
ANA results were available in 81.7% of cases, and almost 
half of these were positive (44.8%).
Incidence rates for dLe
Based on the primary case definition, we identified 41 
incident cases diagnosed with pDLE, with evidence of 
a diagnosis by a rheumatologist or dermatologist for 
most (26) (table 3). The overall crude and age- adjusted 
pDLE incidence rates were 0.9 (95% CI 0.6 to 1.2) and 
0.8 (95% CI 0.6 to 1.1) per 100 000 person- years. Age- 
adjusted rates differed by sex and were approximately 
four times higher for women compared with men 
(p≤0.0002). The incidence of pDLE differed by race/
ethnicity (p<0.0001) with the highest age- adjusted rates 
among non- Latino blacks (2.3) followed by Latinos 
(1.0), non- Latino Asians (0.6) and non- Latino whites 
(0.3). Based on capture–recapture analysis, we esti-
mated an additional 11.4 cases of pDLE, indicating that 
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21.8% of cases may have been missed. With capture–
recapture adjustment, the overall incidence of DLE 
increased to 1.3 (95% CI 0.6 to 2.0) and among non- 
Latino blacks increased to 4.0 (95% CI 2.1 to 5.8). With 
the secondary case definition, the overall crude and age- 
adjusted pDLE incidence rates were lower, at 0.5 (95% 
CI 0.4 to 0.8) and 0.5 (95% CI 0.3 to 0.7) per 100 000 
person- years. Disparities were again seen by sex, with 
rates among women approximately eight times higher 
than among men (p=0.0002), and race/ethnicity, with 
higher rates among non- Latino blacks (p<0.0001).
The average age (±SD) at diagnosis among incident 
pDLE cases meeting the primary case definition was 
45.7 (±16.3) years among women and 40.6 (±20.70) 
years among men. Average age (±SD) at diagnosis was 
highest among non- Latino whites (63.4±24.1) followed 
by Latinos (45.8±16.6), non- Latino Asians (45.3±8.5) 
and non- Latino blacks (36.7±8.6). Age- specific rates 
suggested a similar pattern, with a higher rate among 
those aged 40–59, but numbers were too small to 
provide reliable estimates.
Among incident cases meeting the secondary case defi-
nition, 50.0% had discoid rash located above the neck 
and 11.5% had generalised discoid rash. Over one- third 
(38.5%) had no further location information available. 
Among cases with ANA results available (84.6%), 45.5% 
were positive. As with prevalent cases, biopsy confirma-
tion of pDLE was rare, with evidence found for only 3.8% 
of incident cases.
dIsCussIOn
Our analysis of the MLSP dataset provides prevalence 
and incidence estimates of pDLE among Manhattan 
residents overall and for the major racial/ethnic popula-
tions in the USA. Based on our primary case definition, 
the age- adjusted prevalence and incidence of pDLE in 
Manhattan were 6.5 (95% CI 5.2 to 7.7) and 0.8 (95% CI 
0.6 to 1.1) per 100 000 person- years. Capture–recapture 
adjustment increased prevalence and incidence rates by 
38.5% and 62.5%, respectively. Prevalence of pDLE was 
significantly higher among non- Latino blacks and Latinos 
compared with non- Latino Asians and non- Latino whites. 
The incidence of pDLE was higher among non- Latino 
blacks compared with the other racial/ethnic groups. 
These racial disparities mirrored the pattern of DLE seen 
among SLE cases, with non- Latino black SLE cases having 
the highest percentage of DLE.1
There are limited studies on the epidemiology of pDLE 
and most focus on various forms cutaneous lupus erythe-
matosus (CLE), including pDLE. A US- based study from 
Olmsted County, Minnesota, reported a population- based 
prevalence estimate for CLE of 70.4 per 100 000.17 The 
same study provided an incidence rate of CLE at 4.2 per 
100 000. More than half (55%) of the incident cases were 
reported to have pDLE, suggesting a higher incidence of 
pDLE than we found in our analysis. Several other studies 
have reported incidence rates of pDLE, including a study 
from Sweden and one from French Guiana.17 18 The 
Swedish study provided a pDLE rate of 3.2 per 100 00018 
while the study from French Guiana, with a predomi-
nantly African population, reported an annual chronic 
CLE incidence of 2.6 per 100 000 population (of which 
90% were pDLE).19 In line with our findings, both the 
Minnesota study as well as the Swedish study found that 
prevalent and incident pDLE were higher among women 
compared with men and most common in middle- aged 
women.7 17 18 The Minnesota study also reported rates of 
CLE by race/ethnicity,17 but these rates are not compa-
rable given the predominantly white population (90.3%) 
included in that analysis.
Recently, the Georgia Lupus Registry (GLR), one 
of the five funded CDC registries, published their inci-
dence estimates of primary chronic CLE and pDLE in a 
predominantly white and black population from Fulton 
and DeKalb counties in Georgia.7 The GLR age- adjusted 
and capture–recapture adjusted estimates of pDLE inci-
dence were 3.7 (95% CI 3.2 to 4.3) and 4.0 (95% CI 3.5 
to 4.7) per 100 000 person- years. In line with our findings, 
the GLR also found higher rates among blacks compared 
with whites and among women compared with men. 
However, the GLR did not present estimates for other 
racial/ethnic groups, and to our knowledge, there are no 
other population- based studies that present pDLE find-
ings among more diverse populations.
Although the GLR and MLSP used similar methods, 
there were important differences that likely contrib-
uted to differences in incidence findings. The GLR 
approached both dermatologists and dermatopa-
thology laboratories, which were not approached by the 
MLSP. For the GLR, those case finding sources yielded 
70 (36.8%) cases, with 27 cases that were only found in 
dermatology practices and 43 that were only found in 
dermatopathology laboratories with chronic CLE that 
were not captured by other case finding sources.7 There 
were 25 dermatology practices in the GLR catchment 
area, while there were approximately 350 identified 
within Manhattan during the MLSP planning. Given 
our primary focus on SLE and limited resources avail-
able to abstract from such a large number of physicians, 
the MLSP did not approach dermatology practices. This 
is an obvious limitation to a study focused on capturing 
a primary cutaneous manifestation of lupus and likely 
resulted in an underestimate of the MLSP incidence 
and prevalence estimates of pDLE. In addition, our esti-
mates are biased towards cases requiring hospitalisation 
or rheumatology evaluation, which may also account for 
the low percentage of biopsies available from our case 
finding sources. The low percentage of biopsies found 
in the charts does not necessarily imply that there was a 
low rate of biopsies done by physicians treating patients 
in the MLSP catchment area. Rather this finding 
reflects the fact that biopsy results were not readily 
identified in the charts using the MLSP methodology, 
likely due to the fact that dermatology offices were not 
recruited to this study. Including cases that were only 
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found through hospitalisation or by a rheumatologist 
may have biased our case finding towards sicker cases 
that may have been in the early stages of SLE even if 
they did not fulfil ACR criteria for SLE. Thus, patients 
with DLE in evolution towards SLE would be consid-
ered in this study as pDLE. There were several limita-
tions regarding the development of the MLSP that 
have been previously acknowledged and could have 
accounted for under- ascertainment of prevalent and 
incident cases.1 9 Those included lack of participation 
from one quarter of rheumatologists and two hospitals 
in the catchment area, including the Veteran’s Admin-
istration Hospital, which may have specifically under- 
identified men diagnosed with pDLE. In addition, cases 
would have been missed if they lived in Manhattan but 
sought care in other boroughs or a neighbouring state. 
Additional limitations of the MLSP resulted from the 
tremendous differences across medical systems of case- 
finding sources and abstracting several years after the 
surveillance period.1 9 Additional limitations pertain 
to assigning race and ethnicity based on administra-
tive and medical records which have been previously 
described.1 9
Despite these limitations, our analyses benefited from 
the design and composition of the MLSP, a population- 
based registry with a diverse catchment population.1 
This design allowed us to estimate rates of DLE among a 
larger group of racial/ethnic categories than have been 
previously reported. The partnership with the DOHMH 
allowed us to collect information from several case- 
finding sources and facilitated more complete clinical 
information on many cases. In addition, capture–recap-
ture analyses were conducted to estimate missed cases. 
Finally, our abstractors all had medical backgrounds, 
which helped during training and provided an advantage 
during extensive review of medical records to identify 
criteria and manifestations of SLE.1
In conclusion, data from our large population- based 
registry provide epidemiological estimates for pDLE for 
the major racial/ethnic populations in the USA and reveal 
substantial disparities by sex and race/ethnicity in pDLE 
among Manhattan residents. These findings add support 
to the limited existing epidemiology of this understudied 
disease, confirming evidence of similar disparities among 
patients with SLE with DLE and suggesting non- Latino 
blacks are disproportionately affected whether they have 
the systemic or primary form.
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